The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
作者： H Suen , R Brown , S Yang , P J Ho , J Gibson
DOI: 10.1038/LEU.2015.104
关键词: Blockade 、 Multiple myeloma 、 Internal medicine 、 Interleukin 21 、 Biology 、 Immune checkpoint 、 Leukemia 、 Immunology 、 CTLA-4 、 Hematology 、 Lymphoma
摘要: The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors a phase 1 study
nature.com
sci-hub.se 参考文章(8)
Hayley Suen, Douglas E Joshua, Ross D Brown, Shihong Yang, Pasquale Mario Barbaro, P Joy Ho, John Gibson, Protective Cytotoxic Clonal T-Cells in Myeloma Have the Characteristics of Telomere-Independent Senescence Rather Than an Exhausted or Anergic Phenotype: Implications for Immunotherapy Blood. ,vol. 124, pp. 3367- 3367 ,(2014) , 10.1182/BLOOD.V124.21.3367.3367
Harry Ostrer, Peter K. Gregersen, Franak Batliwalla, Joanita Monteiro, Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. Journal of Immunology. ,vol. 156, pp. 3587- 3590 ,(1996)
A Ray, D S Das, Y Song, P Richardson, N C Munshi, D Chauhan, K C Anderson, Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells Leukemia. ,vol. 29, pp. 1441- 1444 ,(2015) , 10.1038/LEU.2015.11
Daniel M.-Y. Sze, Gillian Giesajtis, Ross D. Brown, Maria Raitakari, John Gibson, Joy Ho, Alan G. Baxter, Barbara Fazekas de St Groth, Antony Basten, Douglas E. Joshua, Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood. ,vol. 98, pp. 2817- 2827 ,(2001) , 10.1182/BLOOD.V98.9.2817
C Bryant, H Suen, R Brown, S Yang, J Favaloro, E Aklilu, J Gibson, P J Ho, H Iland, P Fromm, N Woodland, N Nassif, D Hart, D E Joshua, Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance Blood Cancer Journal. ,vol. 3, ,(2013) , 10.1038/BCJ.2013.34
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M. Zaretsky, Alexis Desrichard, Logan A. Walsh, Michael A. Postow, Phillip Wong, Teresa S. Ho, Travis J. Hollmann, Cameron Bruggeman, Kasthuri Kannan, Yanyun Li, Ceyhan Elipenahli, Cailian Liu, Christopher T. Harbison, Lisu Wang, Antoni Ribas, Jedd D. Wolchok, Timothy A. Chan, Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma The New England Journal of Medicine. ,vol. 371, pp. 2189- 2199 ,(2014) , 10.1056/NEJMOA1406498
Ross D. Brown, Andrew Spencer, Phoebe Joy Ho, Nola Kennedy, Karieshma Kabani, Shihong Yang, Daniel M. Sze, Esther Aklilu, John Gibson, Douglas E. Joshua, Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia & Lymphoma. ,vol. 50, pp. 1860- 1864 ,(2009) , 10.3109/10428190903216804
Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma C. Scott, Ahmad Halwani, Martin Gutierrez, Michael M. Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav V. Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, Su Young Kim, Margaret A. Shipp, Ivan Borrello, John Timmerman, Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies Blood. ,vol. 124, pp. 291- 291 ,(2014) , 10.1182/BLOOD.V124.21.291.291